Scientists Say They’ve Figured Out a Way to Reprogram the Pancreas to Produce GLP-1s Without Ozempic
Scientists say they’ve come up with a way for the body to produce its own store of glucagon-like peptide-1 (GLP-1). GLP-1 is the naturally produced hormone whose function is being mimicked by drugs like semaglutide and tirzepatide, the active ingredients in popular and highly effective weight-loss drugs like Wegovy and Zepbound. As CNN reports, two […]
GLP-1 Drugs Like Ozempic Work, but New Research Reveals a Major Catch
Three new Cochrane reviews find evidence that GLP-1 drugs lead to clinically meaningful weight loss, though industry-funded studies raise concerns. Three new reviews from Cochrane have found that GLP-1 medications can lead to significant weight loss, though questions remain about the influence of industry-funded research. Commissioned by the World Health Organization (WHO), these reviews will […]
Do you take a GLP-1 for alternative uses? Tell us about it.
Some semaglutide users experience benefits beyond weight loss. Are you one of them?
Is There a Future for Viking Therapeutics?
Key Points Viking has initiated an exciting new phase 1 study combining an oral and subcutaneous formulation of a weight loss drug. The phase 1 trial results are expected next year, with the Phase 3 (subcutaneous) trial results scheduled for 2027. 10 stocks we like better than Viking Therapeutics › After the release of the […]
Novo Nordisk selloff an opportunity if markets slump
Novo Nordisk selloff an opportunity if markets slump Novo Nordisk A/S Sponsored ADR Class B BATS:NVO Blueberry Markets are stretched. Tech and AI have run hot. If sentiment breaks, investors will pivot fast. Novo Nordisk offers safety, scale, and cashflow. But this isn’t a flawless story. Novo’s stock has pulled back. Some of that is […]
Anyone know what will happen with Metsera (MTSR) after the Pfizer acquisition is finalized?
As some of you may know there has been a bidding war between Pfizer and Novo Nordisk for the acquisition of Metsera. The prices of the three stocks experienced a significant increase amid the news of TrumpRX and the discounted prices of GLP-1 drugs. I’m just curious what will happen to Metsera once the deal […]
Did Pfizer overpay for Metsera? (10B deal)
To quote a sage There’s no such thing as a bad product, only a bad price Pfizer’s previous acqusition was Seagen on Dec 14 2023 for 43B. To put the deals in comparision Seagen Metsera Cost 43B 10B Focus Oncology Obesity (GLP-1) FDA Approved Drugs Adcetris, Padcev None The entire Metsera deal hinges on MET-097i […]
GLP-1 Use Prior to Pregnancy Tied to Lower Gestational Diabetes Risk
(MedPage Today) — ATLANTA — Women who had been taking GLP-1 receptor agonist medications prior to becoming pregnant had a lower risk of gestational diabetes but not pre-eclampsia during pregnancy, according to a small retrospective cohort study…
Novel GLP-1 Drug on Attack Path Against Very High Triglycerides
(MedPage Today) — NEW ORLEANS — An investigational triple-receptor agonist made some headway in patients with severe hypertriglyceridemia, a phase II study showed. One Chinese cohort had triglycerides slashed from around 800 mg/dL at baseline…
Pfizer wins $10B bidding war for obesity drug developer Metsera in major pharmaceutical acquisition
Pfizer has won a $10 billion deal to acquire the fast-rising obesity drug developer Metsera, ending a fierce bidding war with Danish rival Novo Nordisk. Metsera accepted a sweetened offer from Pfizer late Friday, citing U.S. antitrust risks in Novo’s bid that it had previously called superior, according to Reuters. The Danish obesity-drug giant said […]